Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade : Results of the GIM 13-AMBRA Study
GIM 13-AMBRA is a longitudinal cohort study aimed at describing therapeutic strategies and the relative outcome parameters in 939 HER2-ve MBC patients. Taxanes-based regimens, or taxanes + targeted agents, mainly Bevacizumab, were the preferred first choice in both Luminal (30.2%) and TNBC (33.3%) patients. The median PFS1 was 12.5 months (95% CI 16.79-19.64), without any significant difference according to subtypes, while the median Time to first Treatment Change (TTC1) was significantly lower in TNBC patients (7.7 months-95% CI 5.7-9.2) in comparison to Luminal A (13.2 months, 95% CI 11.7-15.1) and Luminal B patients (11.8 months, 95% CI 10.3-12.8). PFS2 was significantly shorter in TNBC patients (5.5 months, 95% CI 4.3-6.5 vs. Luminal A-9.4, 95% CI 8.1-10.7, and Luminal B-7.7 95% CI 6.8-8.2, F-Ratio 4.30, p = 0.014). TTC2 was significantly lower in patients with TNBC than in those with the other two subtypes. The median OS1 was 35.2 months (95% CI 30.8-37.4) for Luminal A patients, which was significantly higher than that for both Luminal B (28.9 months, 95% CI 26.2-31.2) and TNBC (18.5 months, 95% CI 16-20.1, F-ratio 7.44, p = 0.0006). The GIM 13-AMBRA study is one of the largest collections ever published in Italy and provides useful results in terms of time outcomes for first, second, and further lines of treatment in HER2- MBC patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Cancers - 16(2023), 1 vom: 25. Dez. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
HER2 negative |
|---|
| Anmerkungen: |
Date Revised 14.01.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers16010117 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36692124X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36692124X | ||
| 003 | DE-627 | ||
| 005 | 20240114235044.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers16010117 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1259.xml |
| 035 | |a (DE-627)NLM36692124X | ||
| 035 | |a (NLM)38201545 | ||
| 035 | |a (PII)117 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cazzaniga, Marina Elena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade |b Results of the GIM 13-AMBRA Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a GIM 13-AMBRA is a longitudinal cohort study aimed at describing therapeutic strategies and the relative outcome parameters in 939 HER2-ve MBC patients. Taxanes-based regimens, or taxanes + targeted agents, mainly Bevacizumab, were the preferred first choice in both Luminal (30.2%) and TNBC (33.3%) patients. The median PFS1 was 12.5 months (95% CI 16.79-19.64), without any significant difference according to subtypes, while the median Time to first Treatment Change (TTC1) was significantly lower in TNBC patients (7.7 months-95% CI 5.7-9.2) in comparison to Luminal A (13.2 months, 95% CI 11.7-15.1) and Luminal B patients (11.8 months, 95% CI 10.3-12.8). PFS2 was significantly shorter in TNBC patients (5.5 months, 95% CI 4.3-6.5 vs. Luminal A-9.4, 95% CI 8.1-10.7, and Luminal B-7.7 95% CI 6.8-8.2, F-Ratio 4.30, p = 0.014). TTC2 was significantly lower in patients with TNBC than in those with the other two subtypes. The median OS1 was 35.2 months (95% CI 30.8-37.4) for Luminal A patients, which was significantly higher than that for both Luminal B (28.9 months, 95% CI 26.2-31.2) and TNBC (18.5 months, 95% CI 16-20.1, F-ratio 7.44, p = 0.0006). The GIM 13-AMBRA study is one of the largest collections ever published in Italy and provides useful results in terms of time outcomes for first, second, and further lines of treatment in HER2- MBC patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HER2 negative | |
| 650 | 4 | |a metastatic breast cancer | |
| 650 | 4 | |a overall survival | |
| 650 | 4 | |a progression free survival | |
| 650 | 4 | |a time to treatment change | |
| 700 | 1 | |a Pronzato, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Amoroso, Domenico |e verfasserin |4 aut | |
| 700 | 1 | |a Bernardo, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Biganzoli, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Bisagni, Giancarlo |e verfasserin |4 aut | |
| 700 | 1 | |a Blasi, Livio |e verfasserin |4 aut | |
| 700 | 1 | |a Bria, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Cognetti, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Crinò, Lucio |e verfasserin |4 aut | |
| 700 | 1 | |a De Laurentiis, Michelino |e verfasserin |4 aut | |
| 700 | 1 | |a Del Mastro, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a De Placido, Sabino |e verfasserin |4 aut | |
| 700 | 1 | |a Beano, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Ferraù, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Foladore, Silva |e verfasserin |4 aut | |
| 700 | 1 | |a Forcignanò, Rosachiara |e verfasserin |4 aut | |
| 700 | 1 | |a Gamucci, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Garrone, Ornella |e verfasserin |4 aut | |
| 700 | 1 | |a Gennari, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Giordano, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Giotta, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Giovanardi, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Latini, Luciano |e verfasserin |4 aut | |
| 700 | 1 | |a Livi, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Marchetti, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Mattioli, Rodolfo |e verfasserin |4 aut | |
| 700 | 1 | |a Michelotti, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Montemurro, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Putzu, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Riccardi, Ferdinando |e verfasserin |4 aut | |
| 700 | 1 | |a Ricciardi, Giuseppina |e verfasserin |4 aut | |
| 700 | 1 | |a Romagnoli, Emanuela |e verfasserin |4 aut | |
| 700 | 1 | |a Sarobba, Giuseppina |e verfasserin |4 aut | |
| 700 | 1 | |a Spazzapan, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Tagliaferri, Pierosandro |e verfasserin |4 aut | |
| 700 | 1 | |a Tinari, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Tonini, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Turletti, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Verusio, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Zambelli, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Mustacchi, Giorgio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 16(2023), 1 vom: 25. Dez. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:1 |g day:25 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers16010117 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 1 |b 25 |c 12 | ||